|
KMID : 0391520150230030085
|
|
Journal of the Korean Child Neurology Society
2015 Volume.23 No. 3 p.85 ~ p.90
|
|
|
Comparison of the Therapeutic Effect of Topiramate according to the Type of Migraine - Is It Possible to Select Type-Specific Drug for Preventive Treatment of Migraine? -
|
|
Ji Yang-Hyun
Lee In-Seol
Lee Jun-Hwa
Cho Kyung-Rae
|
|
|
Abstract
|
|
|
Purpose: The purpose of this study was to evaluate a specific effect of topiramate in
accordance to the type of migraine.
Method: A total of 73 children and adolescents who had newly diagnosed chronic
migraine and followed up for more than 1 year after the termination of treatment were
involved in the study. All patients were treated by taking topiramate and intervention
of behavior therapies simultaneously at first. Start dose of topiramate was 25 mg/day
and the dose was increased to 100 mg/day, according to patient’s need. We examined
whether topiramate has the type-specific effect or not by analysing of the change of
number of migraine attacks for more than 1 year after termination of treatment in
migraine without aura (MOA) group and migraine with aura (MA) group.
Results: 67.4% of patients of MA and 33.3% of patients of MOA were cured(P=0.004).
Average dosage of topiramate were 50.0±23.6 in MOA group and 30.2±10.3 mg in MA
group. Therefore the patients with MA took less dose of topiramate than the patients
with MOA (P=0.001). Average frequency of migraine attack were 22.4±5.2/month in
MOA group and 21.4±5.6 in MA before treatment. But the frequency was markedly
decreased as 3.9±6.3/month in MOA group and 1.3±3.4/month respectively(P=0.046).
The taking time to improvement were 22.0±19.3 days in MOA group and 9.5±4.8 days
in MA group, therefore, the time to be required for improvement was shorter in the
group of MA than MOA in patients of the cured and the partially cured(P=0.001, 0.017,
respectively). No correlation was observed between patients’ age and topiramate dosage
in the cured and partially cured group(r=-0.098, P=0.554).
Conclusion: The possibility of improvement was higher in the patients of MA than in
MOA. The patients with MA took less dose of topiramate than MOA. The frequency
of migraine attack was decreased more in the group of MA. And the time to be
required for improvement was shorter in the group of MA than in MOA. Therefore
all results taken together, it is concluded that topiramate has specific effect for MA
|
|
|
KEYWORD
|
|
|
Migraine, Topiramate
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|